We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Market for MicroRNA Tools and Services Expected to More than Double

By LabMedica International staff writers
Posted on 16 Sep 2013
Due to the rapid growth in microRNA (miRNA) research, the markets for reagents and instrumentation in this field as well as for miRNA service providers are expected to more than double over the next several years.

The growth of therapeutic and diagnostic enterprises, higher research funding, and increased outsourcing to contract research organizations should present immense opportunities for the miRNA tools and services market.

Data released in the new Frost & Sullivan (Mountain View, CA, USA) report "Global Analysis of MicroRNA Tools and Services Market" revealed that the market for reagents and instrumentation earned revenues of 110.0 million USD in 2012 and estimated this to more than double to reach 247.7 USD million in 2017. More...


The miRNA services market, which caters to academic and research institutes, core facilities, and pharmaceutical and biotech companies, earned revenues of 35.1 million USD in 2012, and this is expected to grow to 63.3 million USD in 2017.

Of the various miRNA technologies, which include quantitative real-time polymerase chain reaction (qRT PCR), microarrays, and functional tools, qRT PCR remains the fastest growing, while microarray is gradually being replaced by next-generation sequencing platforms.

"As miRNA research evolves globally and more efficient products are required, the space is burgeoning with technology innovations," said Divyaa Ravishankar, senior research analyst at Frost & Sullivan. "Strategic alliances for product development are taking place, resulting in novel kits for qPCR and new mimics and inhibitors that help researchers shorten their project timeline and get more funding. To sustain product value until then, market participants must continue to offer technology improvements and differentiated features, and strategically compete without making deep pricing cuts that may irreversibly damage market potential. Providing complete workflow solutions and discounts when a customer purchases products along with several different portfolios will simplify purchasing and attract new customers."

Related Links:

Frost & Sullivan



New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Serological Pipet Controller
PIPETBOY GENIUS
New
Blood Glucose Test Strip
AutoSense Test
New
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.